Connect Biopharma Holdings (CNTB) EBITDA (2024 - 2026)

Connect Biopharma Holdings (CNTB) has reported EBITDA for 3 consecutive years, with -$19.6 million the latest figure, recorded in Q1 2026.

• Quarterly EBITDA fell 71.29% year-over-year to -$19.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$66.2 million (down 211.45% YoY) and the FY2025 annual result came in at -$58.1 million, down 158.66% from the prior year.
• EBITDA slipped to -$19.6 million in Q1 2026 per CNTB's latest filing, from -$15.5 million in the prior quarter.
• Over the last five years, EBITDA for CNTB reached as high as $13.6 million in Q2 2024 and fell as low as -$19.6 million in Q1 2026.
• A 3-year average of -$11.1 million and a median of -$13.4 million in 2025 frame the typical range for EBITDA.
• The largest YoY upside for EBITDA was 9.39% in 2025 against a maximum downside of 198.37% in 2025.
• Year by year, EBITDA stood at -$9.6 million in 2024, then tumbled by 61.41% to -$15.5 million in 2025, then declined by 26.28% to -$19.6 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$19.6 million, -$15.5 million, and -$17.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.